|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||44.83 - 49.06|
|52 Week Range||27.77 - 116.91|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.20|
Protracted drawdowns in the stock market are unnerving, to say the least. Two of my personal favorites in this buyer's market are AMC Entertainment Holdings (NYSE: AMC) and Beam Therapeutics (NASDAQ: BEAM). AMC Entertainment Holdings' underlying fundamentals and near-term growth prospects aren't going to win over many classic value investors.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at 4:00 p.m. CEST at the Federation of American Soc
A look at the shareholders of Beam Therapeutics Inc. ( NASDAQ:BEAM ) can tell us which group is most powerful...